Autologous stem cell transplant in ALL: Who should we be transplanting in first remission?

Bone Marrow Transplantation

Volumn 37, Issue 11, 2006, Pages 989-995

  Mato, A R ^a   Luger, Selina M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Acute lymphoblastic leukemia; Autologous stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; IMATINIB; MAFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW PURGING; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; SALVAGE THERAPY; TREATMENT OUTCOME; WHOLE BODY RADIATION;

BONE MARROW PURGING; CLINICAL TRIALS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; NEOPLASM, RESIDUAL; PATIENT SELECTION; RECURRENCE; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33646809779     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705370     Document Type: Review

References (41)

1. Hahn T, Wall D, Camitta B, Davies S, Dillon H, Gaynon P et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: An evidence-based review. Biol Blood Marrow Transplant 2005; 11: 823-861.
2. McGovern Jr JJ, Russell PS, Atkins L, Webster EW. Treatment of terminal leukemic relapse by total-body irradiation and intravenous infusion of stored autologous bone marrow obtained during remission. N Engl J Med 1959; 260: 675-683.
3. Fiere D, Lepage E, Sebban C, Boucheix C, Gisselbrecht C, Vernant JP et al. Adult acute lymphoblastic leukemia: A multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1993; 11: 1990-2001.
4. Gorin NC, Aegerter P, Auvert B. Autologous bone marrow transplantation for acute leukemia in remission: An analysis of 1322 cases. Haematol Blood Transfus 1990; 33: 660-666.
5. Tiley C, Powles R, Treleaven J, Catovsky D, Milan S, Teo CP et al. Feasibility and efficacy of maintenance chemotherapy following autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia. Bone Marrow Transplant 1993; 12: 449-455.
6. Blaise D, Attal M, Pico JL, Reiffers J, Stoppa AM, Bellanger C et al. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leuk Lymphoma 1997; 25: 469-478.
7. Simonsson B, Burnett AK, Prentice HG, Hann IH, Brenner MK, Gibson B et al. Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia 1989; 3: 631-636.
8. Doney K, Buckner CD, Fisher L, Petersen FB, Sanders J, Appelbaum FR et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant 1993; 12: 315-321.
9. Carey PJ, Proctor SJ, Taylor P, Hamilton PJ. Autologous bone marrow transplantation for high-grade lymphoid malignancy using melphalan/ irradiation conditioning without marrow purging or cryopreservation. The Northern Regional Bone Marrow Transplant Group. Blood 1991; 77: 1593-1598.
10. Lambertenghi Deliliers G, Mozzana R, Annaloro C, Butti C, Della Volpe A, Oriani A et al. Long-term results of autologous bone marrow transplantation in adult acute lymphoblastic leukemia. Leuk Lymphoma 1993; 11: 419-425.
11. Gilmore MJ, Hamon MD, Prentice HG, Katz F, Slaper-Cortenbach IC, Hunter AE et al. Failure of purged autologous bone marrow transplantation in high risk acute lymphoblastic leukaemia in first complete remission. Bone Marrow Transplant 1991; 8: 19-26.
12. Vey N, Blaise D, Stoppa AM, Bouabdallah R, Lafage M, Sainty D et al. Bone marrow transplantation in 63 adult patients with acute lymphoblastic leukemia in first complete remission. Bone Marrow Transplant 1994; 14: 383-388.
13. Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol 2004; 22: 4075-4086.
14. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc 2005; 80: 1517-1527.
15. Bassan R, Lerede T, Di Bona E, Rambaldi A, Rossi G, Pogliani E et al. Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia. Br J Haematol 1999; 104: 755-762.
16. Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: A GOELAMS trial. Blood 2004; 104: 3028-3037.
17. Gorin NC. Autologous stem cell transplantation in acute lymphocytic leukemia. Stem Cells 2002; 20: 3-10.
18. Powles R, Sirohi B, Treleaven J, Kulkarni S, Tait D, Singhal S et al. The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia. Blood 2002; 100: 1641-1647.
19. Hallbook H, Hagglund H, Stockelberg D, Nilsson PG, Karlsson K, Bjorkholm M et al. Autologous and allogeneic stem cell transplantation in adult ALL: The Swedish Adult ALL Group experience. Bone Marrow Transplant 2005; 35: 1141-1148.
20. Egerer G, Goldschmidt H, Zoz M, Ho AD. Autologous bone marrow transplantation in adult patients with acute lymphoblastic leukemia. Leuk Lymphoma 2003; 44: 9-14.
21. Martin H, Atta J, Zumpe P, Eder M, Elsner S, Rode C et al. Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia. Exp Hematol 1995; 23: 1612-1618.
22. Uckun FM, Kersey JH, Vallera DA, Ledbetter JA, Weisdorf D, Myers DE et al. Autologous bone marrow transplantation in high-risk remission T-lineage acute lymphoblastic leukemia using immunotoxins plus 4-hydroperoxycyclophosphamide for marrow purging. Blood 1990; 76: 1723-1733.
23. Uckun FM, Kersey JH, Haake R, Weisdorf D, Ramsay NK. Autologous bone marrow transplantation in high-risk remission B-lineage acute lymphoblastic leukemia using a cocktail of three monoclonal antibodies (BA-1/CD24, BA-2/CD9, and BA-3/CD10) plus complement and 4-hydroperoxycyclophosphamide for ex vivo bone marrow purging. Blood 1992; 79: 1094-1104.
24. Uckun FM, Myers DE. Allograft and autograft purging using immunotoxins in clinical bone marrow transplantation for hematologic malignancies. J Hematother 1993; 2: 155-163.
25. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339: 591-598.
26. Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96: 2691-2696.
27. Chen JS, Coustan-Smith E, Suzuki T, Neale GA, Mihara K, Pui CH et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 2001; 97: 2115-2120.
28. Morishima Y, Miyamura K, Kojima S, Ueda R, Morishita Y, Sao H et al. Autologous BMT in high risk patients with CALLA-positive ALL: Possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement. Bone Marrow Transplant 1993; 11: 255-259.
29. Mizuta S, Ito Y, Kohno A, Kiyoi H, Miyamura K, Tanimoto M et al. Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group. Bone Marrow Transplant 1999; 24: 777-784.
30. Foroni L, Mitchell W, Rai LJ, Casanova A, Patel B, Richards S et al. Value of Molecular Monitoring for Minimal Residual Disease Preceding Autologous SCT Following Diagnosis of B Cell Acute Lymphoblastic Leukemia in Patients Treated with the MRC UKALL12 Protocol. Blood 2005; 106: 423a (Abstract 1468).
31. Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the prospective multicenter LALA-94 trial. Blood 2002; 100: 2357-2366.
32. Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Gokbuget N, Atta J et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) treated with imatinib. Blood 2004; 103: 1495-1498.
33. Thiebaut A, Vernant JP, Degos L, Huguet FR, Reiffers J, Sebban C et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. Hematol Oncol Clin North Am 2000; 14: 1353-1366.
34. Rowe JM, Buck G, Burnett AK, Chopra R, Wiernik PH, Richards SM et al. Induction therapy for adults with acute lymphoblastic leukemia (ALL): Results of nearly 1,400 patients from the international ALL trial (MRC UKALL XII/ECOG E2993). Blood 2003; 102: 224a (Abstract 785).
35. Goldstone AH, Lazarus JH, Richards SM, Litzow MR, Chopra R, Burnett A et al. The Outcome of 551 1st CR Transplants in Adult ALL from the UKALL XII/ECOG 2993 Study. Blood 2004; 104: 178a (Abstract 615).
36. Goldstone AH, Chopra R, Buck G, Richards M, Franklin IM, Lazarus HM et al. The outcome of 267 Philadelphia positive adults in the international UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years. Blood 2003; 102: 80a (Abstract 268).
37. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Singhal S. High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission. Bone Marrow Transplant 2004; 33: 1107-1114.
38. Singhal S, Powles R, Treleaven J, Kulkarni S, Horton C, Tait D et al. Sequential high-dose therapy of adult acute lymphoblastic leukemia: Blood cell autografts with maintenance therapy in first remission and allografting in second remission for relapsing patients. Blood 1996; 88: 125a (Abstract 490).
39. Ringden O, Labopin M, Gorin NC, Meloni G, Blaise D, Reiffers J et al. The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 2000; 25: 1053-1058.
40. Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O'Brien S et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 1999; 86: 1216-1230.
41. Chopra R, Goldstone AH, Buck G, Richards SM, Franklin I, Lazarus HM et al. Adult patients with acute lymphoblastic leukaemia (ALL) who relapse have a dismal outlook: Results from MRC UKALL XII/ECOG 2993 Trial. Blood 2003; 102: 880a (Abstract 3275).